According to a news source, NGM Biopharmaceuticals, Inc. has completed a $50-million Series C financing round that included new investors from the Topspin Fund and existing investors including The Column Group, Prospect Venture Partners, Rho Ventures, and Tichenor Ventures. NGM CEO William Rieflin said, “We remain focused on delivering the next generation of first-in-class therapeutics for the treatment of diabetes and other cardio-metabolic diseases.” Headquartered in South San Francisco, NGM has reportedly raised more than $130 million since it was founded in 2008 and has spent much of its resources and time doing basic research to uncover how hormones and receptors regulate diseases such as diabetes, obesity, muscle wasting, and cardiovascular disorders. See NGM Biopharmaceuticals, Inc. Press Release, July 18, 2013; San Francisco Business Times, July 19, 2013.